Concord Biotech IPO Date, Price, Review
Concord Biotech IPO: Know everything about Concord Biotech IPO. Concord Biotech Limited IPO Date, Concord Biotech IPO Review and analysis. We will discus about Concord Biotech IPO Benefits & Risks. Also, all information related to Concord Biotech IPO like price band, all important dates, issue size, Brockrage Review, and retail quota etc.
Concord Biotech IPO
Concord Biotech Ltd Has filed its DRHP (Draft Red Herring Prospectus) with market regulator SEBI (Securities and Exchange Board of India) to raise around Rs 1551 crore through IPO (Initial public offering).
Concord Biotech IPO will open on 04 August 2023 and close on 08 August 2023. The price band of the Concord Biotech IPO is ₹705 to ₹741. Concord Biotech IPO size is 1551 Crores. The offer includes 0 Crores under fresh issue and 1551 Crores under offer for sale. Concord Biotech IPO QIB quota is 50%, NII quota is 15% and RII quota is 35%. Concord Biotech IPO listing date is 18 August 2023. You can know about Concord Biotech IPO GMP (Grey Market Premium) below.
Concord Biotech has given good financial performance. The company made a profit of ₹240.08 crores in the financial year 2023 (March 2023). The IPO of Concord Biotech will be listed on NSE and BSE. Concord Biotech IPO face value is ₹1 per equity share.
We will talk about Concord Biotech's financials, benefits, and risks of investing in the company.
About Concord Biotech Limited
Concord Biotech Limited is an Indian biotechnology company that specializes in the research, development, and production of active pharmaceutical ingredients (APIs) and intermediates for the pharmaceutical industry. The company is headquartered in Ahmedabad, Gujarat, India.
Concord Biotech focuses on manufacturing high-quality APIs and intermediates using biotechnology processes. The company's expertise lies in producing APIs through fermentation, enzymatic reactions, and other biotechnological methods.
The company offers a diverse range of APIs and intermediates used in various therapeutic areas, including antibiotics, immunosuppressants, statins, and oncology drugs. Concord Biotech serves both domestic and international markets.
Concord Biotech invests significantly in research and development to enhance its product portfolio and develop new and innovative pharmaceutical molecules. Its R&D efforts are aimed at improving existing processes, optimizing yields, and reducing production costs.
Concord Biotech has a significant focus on exports and supplies its APIs and intermediates to pharmaceutical companies worldwide. The company's global reach allows it to tap into a broad customer base and expand its market presence.
Purpose of the offer
- To prepay/repay all or a part of the dues raised by the company.
- To finance capital expenditure requirements.
- To meet general corporate objectives.
Concord Biotech IPO Date and Price Band Details
| IPO Open: | 04 August 2023 |
| IPO Close: | 08 August 2023 |
| Listing Date: | 18 August 2023 |
| Listing On: | NSE & BSE |
| IPO Size: | Approx ₹1551 crores |
| Fresh Issue: | Approx ₹0 crores |
| Offer For Sale: | Approx ₹1551 crores |
| Price Band: | ₹705 to ₹741 per share |
| Face Value: | ₹1 per Equity share |
| QIB Portion: | 50% |
| Retail Portion: | 35% |
| NII Portion: | 15% |
| Employee Res: | Not Disclosed |
Concord Biotech IPO Lot Size Details
| Minimum Lot: | 01 |
| Minimum Lot Size: | 20 Shares |
| Minimum Amount: | ₹14,820 |
| Maximum Lot: | 13 |
| Maximum Lot Size: | 260 Shares |
| Maximum Amount: | ₹192,660 |
Concord Biotech IPO Open, Close, Allotment, and Listing Date
| Ipo Opening Date: | 04 August 2023 |
| IPO Closing Date: | 08 August 2023 |
| Basis of Allotment: | 11 August 2023 |
| Refund Date: | 14 August 2023 |
| Credit to Demat Account: | 17 August 2023 |
| Listing Date: | 18 August 2023 |
Concord Biotech IPO Review
| Happiest Post | Apply |
| Dilip Davda | May Apply |
| Choice Eqe Bro | Apply |
| Reliance Securities | Apply |
| HDFC Securities | Not Rated yet |
| ICICI Direct | Not Rated yet |
| Kotak Securities | Not Rated yet |
| Motilal Oswal | Not Rated yet |
| Sharekhan | Not Rated yet |
You can also check the latest IPO subscription status and IPO allotment status of Concord Biotech IPO on our website.
Concord Biotech Ipo Rating
Review For Listing Gain
Review For Short term
Review For Long term
Strength
- Concord Biotech Limited's focus on biotechnology and its expertise in fermentation and enzymatic reactions can be a significant strength. Biotechnology companies often have the potential to develop innovative products and solutions in the pharmaceutical industry.
- A diverse range of APIs and intermediates catering to various therapeutic areas can provide a revenue stream from multiple sources. A diversified product portfolio can also reduce dependency on a single product or market segment.
- Concord Biotech's emphasis on exports can be an advantage, as it allows the company to tap into a global customer base and benefit from potential growth opportunities in international markets.
- The company has an experienced and dedicated senior management team.
Risks
- The biotechnology and pharmaceutical industries are subject to rigorous regulatory processes and clinical trials. Delays or failures in obtaining regulatory approvals or conducting successful clinical trials can significantly impact the company's product development timelines and financial performance.
- Biotech companies often require substantial investments in research and development. The success of Concord Biotech's products and its ability to stay competitive may depend on its ability to continually invest in R&D.
- The pharmaceutical and biotech sectors are highly competitive, with numerous players vying for market share. Concord Biotech may face competition from other established companies, as well as emerging biotech startups with innovative technologies.
- As with any investment, there is inherent market volatility and uncertainty. Economic conditions, changes in industry dynamics, and global events can influence the stock price of Concord Biotech and other market-related factors.
Concord Biotech Ltd Financials
Concord Biotech Financials(in Crores)
| Year | Total Assets | Revenue | Profit |
|---|---|---|---|
| 2020 | ₹940.52 | ₹543.59 | ₹169.11 |
| 2021 | ₹1182.55 | ₹630.75 | ₹234.89 |
| 2022 | ₹1312.80 | ₹736.35 | ₹174.93 |
| 2023 | ₹1513.98 | ₹888.48 | ₹240.08 |
Promoters
- Sudhir Vaid
- Ankur Vaid
Contact Details of Concord Biotech
NH-8A, Sarkhej- Bavla Highway,
Changodar, Ahmedabad 382213,
Gujarat, India
Telephone: +91 2717-618200
E-mail: sec@harshaengineers.com
Website:www.harshaengineers.com
Concord Biotech Lead Managers
- Kotak Mahindra Capital Company Limited
- Citigroup Global Markets India Private Limited
- Jefferies India Private Limited
Concord Biotech IPO Registrars
C-101, 1st Floor, 247 Park
L.B.S. Marg, Vikhroli (West)
Mumbai 400 083, Maharashtra
Telephone: +91 22 4918 6200
Email: harshaengineers.ipo@linkintime.co.in
Website:www.linkintime.co.in
Conclusion
Please note that the specific strengths and risks associated with investing in Concord Biotech Limited can only be determined by conducting up-to-date research and analysis on the company's financial performance, market position, and industry outlook. In the financial year 2023, the company had a profit of Rs 240.08 crore. The company operates in many different sectors. Our suggestion will be updated when the Concord Biotech Limited IPO starts. Concord Biotech Limited IPO financial details and other information are given above.
Concord Biotech IPO FAQs
How to Apply the Concord Biotech Ltd IPO with Zerodha?
We hope you like this article about Concord Biotech IPO. If you have a query about Concord Biotech IPO then, leave a comment. Here you can also stay updated about the upcoming IPO. Also, you can track IPO performance. Thanks for Visiting. Happy Investing.
0 Comments
We are waiting for your comments. 💙